HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Tennessee AG Settles With Cosmetic Lash-Enhancer Brands; Sales Cease

This article was originally published in The Rose Sheet

Executive Summary

Two cosmetics companies have settled charges filed by Tennessee’s Office of the Attorney General concerning eyelash-enhancement products that require FDA approval, according to the AG’s release. Tennesseans will no longer have access to Nutra Luxe’s Beautylash products or Peter Thomas Roth’s Lashes to Die For as a result of the agreement.

You may also be interested in...



Allergan Continues Legal Sparring With Cosmetic Eyelash-Growth Brands

Latisse marketer Allergan continues to lock horns with cosmetic firms offering non-FDA-approved, prostaglandin-based eyelash-enhancement products, pursuing injunction and damages in California court.

FDA’s Warning To Lash-Growth Firm Shows Risks In Third-Party Claims

An April 18 FDA warning letter to Lifetech Resources LLC demonstrates that cosmetics firms will be held accountable when their websites feature third-party claims and testimonials that cross into drug marketing territory.

Jan Marini Focused On Damage Control Following FDA Seizure Of Eyelash Item

Jan Marini issued a statement Nov. 16 stressing that its Age Intervention Eyelash product has not been manufactured or distributed since September of last year, in response to a release from FDA announcing seizure of the "potentially harmful" product

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS018693

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel